14 Results
Sort By:
Published on May 16, 2024
A novel, bimodal, drug that affects neuroplasticity causes twice the amount of weight loss in obese mice than a GLP-1 agonist alone, researchers have shown. The drug, MK-801, integrates N-methyl-D-aspartate (NMDA) antagonism with glucagon-like peptide-1 (GLP-1) agonism. In mice, it reverses obesity, hyperglycemia and dyslipidemia. The drug’s developers believe that,…
Published on April 11, 2024
In a comprehensive study spanning three Scandinavian countries, researchers from the Karolinska Institute in Sweden have found no significant link between the use of GLP-1 analogues, a popular class of diabetes drugs, and an increased risk of thyroid cancer. Published in The BMJ, the study aims to put to rest…
Published on November 9, 2023
AstraZeneca has licensed ECC5004, an investigational oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA), from Eccogene for the treatment of obesity, type 2 diabetes, and other cardiometabolic conditions. Eccogene will receive an initial upfront payment of $185M and up to $1.825B in future clinical, regulatory, and commercial milestones and tiered…
Published on June 27, 2023
Results presented at the annual American Diabetes Association conference show Eli Lilly’s retatrutide was able to induce up to a 24 percent reduction in body weight in individuals with obesity during almost a year of follow-up in a Phase II trial. As reported in the New England Journal of Medicine…
Published on April 22, 2024
“Next generation” weight loss drug developer Metsera just launched with $290M in funding. Backed by Population Health Partners and ARCH Venture Partners and led by former executives of The Medicines Company, Metsera has a broad portfolio of oral and injectable incretin, non-incretin, and combination therapies designed to address multiple targets.…
Published on March 11, 2024
Novo Nordisk has just taken two big steps toward cementing its lead in the weight loss treatment market. Late last week, the FDA approved a new label expansion for Wegovy (semaglutide), and just before that the company released promising early trial results for its experimental weight loss pill, amycretin. Patients…
Published on March 5, 2024
Novo Nordisk today announced it has notched another win for its GLP-1 agonist semaglutide (Ozempic), this time for reducing cardiovascular disease and slowing kidney disease in diabetic patients. The latest results from the FLOW trial suggest the drug cuts risk of death in this population by as much as 24%. …
Published on December 4, 2023
Roche announced today it is acquiring Carmot Therapeutics for $2.7B up front with potential milestone payments of $400M. Carmot’s R&D portfolio includes clinical stage subcutaneous and oral incretins to treat obesity, as well as a number of preclinical programs. Carmot’s lead program is a Phase-II ready, dual GLP-1/GIP receptor agonist…
Published on May 16, 2022
The U.S. FDA has approved Monjauro (tirzepatide), Eli Lilly’s first-in-class type 2 diabetes drug activating both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). “Given the challenges many patients experience in achieving their target blood sugar goals, today’s approval of Mounjaro is an important advance in the treatment of type…
Published on February 6, 2024
Early data suggest Amgen’s experimental weight-loss drug MariTide (maridebart cafraglutide) produces similar effects but is longer-lasting than current market leaders, and blockbusters, glucagon-like peptide-1 inhibitors Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide). The study was published in Nature Metabolism this week. The lead authors are Murielle M. Véniant…
Published on December 8, 2023
Researchers at Case Western Reserve University say that a class of diabetes drugs used to treat type 2 diabetes may reduce the risk of the development of colorectal cancer (CRC). The drugs, called glucagon-like peptide-1 receptor agonists, or GLP-1 RAs are medications that are given by injection to lower blood…
Published on October 17, 2023
Eli Lilly’s tirzepatide (Mounjaro) led overweight people or people with obesity to lose almost a quarter of their weight in a recent trial that lasted over 72 weeks. Average weight loss was about 60lbs. The drug is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist that…
Published on August 8, 2023
Topline results from the large-scale Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) clinical study released today show that the Novo Nordisk obesity drug reduces the risk of major adverse cardiovascular events by 20 percent. The SELECT trial is the first to demonstrate the…
Published on April 14, 2022
Researchers based at the Children’s Hospital of Philadelphia (CHOP) have developed and trialed a candidate treatment for children with congenital hyperinsulinism, which was successful at reducing bouts of low blood sugar, or hypoglycemia, in a phase IIa trial. Congenital hyperinsulinism is a rare condition affecting less than 1 in 25,000…